Sector Focus

Biotechnology

Caliber has successfully planned with both venture backed private development stage companies and publicly traded biopharmaceutical companies. We understand the unique challenges of emerging companies as well as global biotech organizations and we have developed a keen sense of what it takes to discover and develop biologically derived treatments to enhance the quality of care in markets with substantially under met medical needs.

Clients

Castle Biosciences

Castle Biosciences develops and commercializes diagnostic and prognostic tests for cancers that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. Our first test for uveal melanoma, a rare and deadly eye cancer, is used to identify those at high risk for metastasis. With demonstrated improved accuracy over existing staging and prognostic tools, the test has become the standard of care for uveal melanoma and has successfully secured reimbursement. We are using its innovation as a model for our growing lineup of practice-changing tests, including our newer cutaneous (skin) melanoma prognostic assay. We have active development programs for assays in several other underserved cancers.

Search Projects